Ranking Semantic Associations in Chemical System Biology Space

> Xiao Dong School of Informatics and Computing Indiana University at Bloomington

Presented at FWCS2010, April 26th WWW2010, Raleigh, NC

Chem2Bio2RDF

- www.chem2bio2rdf.org
- Initiated by Prof. Ding (NIH VIVO investigator) at Fall 2009.
- Work done at chemical informatics group (Prof. Wild) at IU.
- Primary goal is to bring chemogenomics data source onto linked data cloud.

Chemogenomics and Chemical Systems Biology





Motivation

- Many important research questions can be boiled down to indentifying crucial associations among biological entities
 - find gene targets which the <u>compound</u> is active against
 - find <u>compounds</u> associated to a certain <u>disease</u> (Alzheimer)
 - find <u>compounds</u> cause a given <u>adverse</u> drug <u>effect</u> (Hypertension)
 - find all the active <u>compounds</u> in PubChem sharing at least two common targets with a FDA approved <u>drug</u>
 - find all the <u>compounds</u> in PubChem active towards at least two targets that are in the same <u>pathway</u>
 - find KEGG <u>pathways</u> containing at least two of the targets associated with a given <u>side effect</u>

Semantic Associations Formally

- Semantic association refers to a sequence of {subject property object} triples that connect two instances
- ρ -path association
- ρ-join association
- ρ -iso association



SemRank by Anyanwu, K. et al. WWW 2005



Multiple Pathway Inhibitor





p -join in chemical systems biology

Two Intriguing Cases



(b) Double ho Path Association, Identify multiple pathway inhibitor



(a) Double ho Join Association, polypharmacology

Polypharmacology

- Conventional drug embraces the dogma "one gene, one drug, one disease"
- Polypharmacology focuses on multi-target drugs
 - Identify target leads to unwanted side effect
 - Enhance therapeutic potency
- Identify compounds sharing targets with drugs of known polypharmacology

Ranking

- Intrinsic metrics
 - Multiple Path Aggregator is applied to promote the special case associated pairs conform to special interests (i.e. multiple pathway inhibitor or polypharmacology)
- Extrinsic metrics
 - Quality
 - Specificity
 - Rarity/Popularity
- Weighted sum taken as the total ranking score
- Evaluation using pubmed literature abstract cooccurrence score

Association Pairs (Compound/ Dexamethasone)

data source	number of associations found	polypharmacology cases found
PubChem Bioassay	1123	2
CTD	318	21
BindDB	117	0
TTD	30	0
MATADOR	0	N/A
QSAR	0	N/A
PharmGKB	0	N/A

Chem/Bio Entity Extraction from PubMed

PMID: 20017669 Title: Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Abstract: Aims: Nevirapine is widely used Abstract: Aims: Nevirapine is widely used to treat Hive infection to prevent mother-to-child transmission; unfortunately adverse drug reactions have been reported. Our aim was to identify genes/variants involved in nevirapine-induced hepatotoxicity MATERIALS & METHODS: Patients from Mozambique, 78 with nevirapine-induced hepatotoxicity and 78 without adverse events were genotyped for ABCB1, CYP2B6, CYP3A4 and CYP3A5 gene variants. We conducted a case-control association study and a association study and а genotype/phenotype correlation analysis. RESULTS: The ABCB1 c.3435C>T SNP was associated with hepatotoxicity (p = 0.038), with the variant T allele showing a protective effect (odds ratio: 0.42). Moreover, four SNPs in the CYP2B6 and CYP3A5 genes resulted significantly correlated with transaminase values. In particular, for the CYP2B6 c.983T>C SNP difference the in the aminotransferase mean values were highly significant between TT and TC genotypes (p < 0.001). CONCLUSION: Our preliminary results confirm the contribution of the ABCB1 c.3435C>T SNP in nevirapineinduced hepatotoxicity risk and, at the same time, suggest the necessity for further studies.



Validation with Literature Co-occurrence

PubChem ID	quality	distinctiveness	specificity	ranking score	
443495	4	3	0	7	
55245	4	3	0	7	
969516	3	2.01	0	5.01	
74990	3	2.01	0	5.01	
5743	2	1.02	1	4.02] 🗸

Acknowledgement

- NIH VIVO project
- Eli Lilly and Company



Extends to LODD and Bio2RDF

